Entrada tightens focus on Duchenne, axes 20% of staff on May 01, 2025 Duchenne ENTR-601 exon Muscular Dystrophy Study on Hold United States Food and Drug Administration +
Avidity's Del-zota Shows Promise in Duchenne Muscular Dystrophy Treatment on March 18, 2025 Creatine Kinase Del-zota DMD Duchenne Dystrophin exon Muscular Dystrophy production RNA safety profile skipping +
FDA Lifts Clinical Hold on Entrada's Duchenne Muscular Dystrophy Drug ENTR-601-44 After Two Years on February 24, 2025 Duchenne ELEVATE-44 ENTR-601 Entrada exon Muscular Dystrophy Phase 1b trial skipping Study on Hold United States Food and Drug Administration +